Welcome to our dedicated page for Foghorn Therapeutics SEC filings (Ticker: FHTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Foghorn Therapeutics Inc. (FHTX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Foghorn is a clinical-stage biotechnology company listed on The Nasdaq Global Market, and its common stock is registered under the symbol FHTX, as reflected in multiple Form 8-K filings.
For investors analyzing FHTX, Form 8-K filings are especially important. Recent 8-Ks have reported quarterly financial results, including collaboration revenue from the company’s strategic agreement with Lilly, research and development and general and administrative expenses, and net loss figures. Other 8-Ks describe material corporate events such as leadership changes in the Chief Financial Officer role, interim CFO appointments through Danforth Advisors, and updates on presentations and investor materials furnished under Regulation FD.
Foghorn also uses 8-K filings to furnish investor presentations and pipeline updates, including detailed summaries of its chromatin-focused programs. These documents outline the status of FHD-909 (LY4050784), a first-in-class SMARCA2 selective inhibitor in Phase 1 trials for SMARCA4-mutated cancers, as well as selective CBP, EP300, and ARID1B degrader programs moving through preclinical and IND-enabling stages. Additional 8-K disclosures cover facility leases in Massachusetts for principal executive offices and research, development, manufacturing, and related uses.
On this page, new SEC filings are captured as they are made available on EDGAR, allowing users to track Foghorn’s current reports, financial updates, and other material events in one place. Stock Titan’s interface is designed to make it easier to review the contents of lengthy filings and locate key items such as results of operations, material agreements, leadership changes, and Regulation FD presentations.
By using this filings hub, investors and researchers can follow how Foghorn Therapeutics reports its financial condition, corporate actions, clinical and preclinical program disclosures, and capital markets activity through official SEC documents, including 8-Ks and any related registration statements referenced in company press releases.
Foghorn Therapeutics is a clinical-stage biotechnology company developing precision medicines that correct abnormal gene expression by targeting the chromatin regulatory system, which is implicated in roughly half of all cancers. Its proprietary Gene Traffic Control® platform combines genomics, epigenomics, AI tools and protein degradation technologies to identify genetically driven dependencies and drug them selectively.
The lead program, FHD-909, is a first-in-class oral SMARCA2-selective inhibitor being developed with Eli Lilly for SMARCA4-mutated cancers, particularly non-small cell lung cancer, with a Phase 1 trial underway after first dosing in October 2024. Foghorn and Lilly are also advancing a SMARCA2 degrader and additional oncology discovery programs.
The pipeline includes selective degraders of CBP, EP300 and ARID1B aimed at tumor types where paralog mutations create synthetic lethal vulnerabilities across solid tumors and hematologic cancers. Management believes the current portfolio could benefit more than 500,000 cancer patients and supports the potential to file four INDs over the next two years. As of December 31, 2025, the company had 106 employees and remains pre-commercial with no approved products, highlighting typical biotechnology risks such as ongoing losses, funding needs, clinical uncertainty and strong competition.
Foghorn Therapeutics reported 2025 results and outlined its oncology pipeline progress and financing. Collaboration revenue rose to
As of
Foghorn Therapeutics Inc. reported that Chief Financial Officer Ryan D. Maynard was granted a stock option to acquire 400,000 shares of common stock at an exercise price of
Foghorn Therapeutics Inc. filed a Form 3 for Chief Financial Officer Maynard Ryan D, providing his initial statement of beneficial ownership in the company’s stock. The filing does not list any specific share transactions, focusing instead on establishing his reporting status as an executive officer.
Foghorn Therapeutics Inc. appointed Ryan D. Maynard as Chief Financial Officer, effective February 23, 2026. He will serve as the company’s principal financial and accounting officer, succeeding interim CFO Jeff Sacher.
Maynard brings more than 25 years of executive finance experience at biopharmaceutical and healthcare companies, including prior CFO roles at Cara Therapeutics, LetsGetChecked, Blade Therapeutics, and Rigel Pharmaceuticals. His employment terms include a $510,000 annual base salary, eligibility for an annual performance bonus targeted at 40% of base salary, a $90,000 signing bonus, and a stock option to purchase 400,000 Foghorn common shares under the 2020 Equity Incentive Plan. The option vests 25% on the first anniversary of grant and the remaining 75% in equal quarterly installments over the following 12 quarters, subject to continued employment.
The company issued a press release highlighting Maynard’s track record in capital markets, strategic transactions, and commercial planning, as well as his ongoing board role at Iovance Biotherapeutics. Foghorn reiterated its focus on developing oncology medicines targeting the chromatin regulatory system and referenced forward-looking statements about its pipeline, clinical trials, and cash runway.
Foghorn Therapeutics Inc. Chief Executive Officer and director Adrian Gottschalk received a new stock option grant. On February 5, 2026, he was awarded an option to purchase 1,075,000 shares of Foghorn Therapeutics common stock at an exercise price of $5.23 per share.
The option vests as to 25% of the underlying shares on February 5, 2027, then 6.25% of the shares vest on the first day of each calendar quarter thereafter. Following this grant, Gottschalk beneficially owns 1,075,000 derivative securities directly.
Foghorn Therapeutics granted Chief People Officer Carlos Costa a stock option award covering 230,000 shares of common stock on January 30, 2026. The option has an exercise price of $5.71 per share and is held directly by Costa.
The option vests over time: 25% of the underlying shares vest on January 30, 2027, with the remaining shares vesting at a rate of 6.25% of the underlying shares on the first day of each calendar quarter thereafter. Following this grant, Costa beneficially owns stock options for 230,000 shares.
Foghorn Therapeutics reported that Chief Legal Officer Michael LaCascia received an award of stock options covering 295,000 shares of common stock at an exercise price of $5.71 per share on January 30, 2026. The option vests 25% on January 30, 2027, then 6.25% of the underlying shares on the first day of each calendar quarter, aligning his compensation with the company’s future share performance.
Foghorn Therapeutics Inc. reported that its Chief Medical Officer, Alfonso Quintas-Cardama, received a grant of stock options on January 30, 2026. The award covers 300,000 stock options with an exercise price of $5.71 per share.
The options relate to common stock and are held directly. Vesting is structured so that 25% of the underlying shares vest on January 30, 2027, with the remaining options vesting at 6.25% of the underlying shares on the first day of each calendar quarter until fully vested. The options expire on January 29, 2036 if not exercised.
Foghorn Therapeutics granted Chief Business Officer Anna Rivkin a stock option to buy 165,000 shares of common stock at
The option vests over time: 25% of the underlying shares vest on January 30, 2027, and the remaining 75% vest in equal quarterly installments of 6.25% of the underlying shares on the first day of each calendar quarter. The option expires on January 29, 2036 if not exercised.